Core Viewpoint - Zai Lab emphasizes the importance of both its China business and global portfolio, indicating a strategic dual-engine approach to growth and innovation [2][3]. Group 1: Company Overview - Zai Lab was founded 11 years ago with a dual focus on commercial opportunities in China and a global portfolio for innovation [3]. - The company has successfully obtained approval for 8 products in China, projecting sales of approximately $460 million [4]. Group 2: Strategic Focus - The company aims to serve as a partner for global biotech firms lacking capabilities in China while also promoting Chinese innovations globally [3]. - The commercial engine of Zai Lab is designed to accelerate growth, reflecting a strategic emphasis on both local and international markets [3].

Group 1 - The article critiques passive small-cap strategies, specifically the iShares S&P Small-Cap 600 Value ETF (IJS), for not adequately screening for quality, which could expose investor capital to risks during market downturns [1] - The Sunday Investor focuses solely on U.S. Equity ETFs and has developed a proprietary ETF Rankings system that evaluates nearly 1,000 ETFs based on various factors including costs, liquidity, risk, size, value, dividends, growth, quality, momentum, and sentiment [1] - The composite score from the ETF Rankings system ranges from 1 to 10, providing an easy-to-understand metric for investors [1]

Group 1 - Totec Resources Ltd. is a capital pool company listed on the TSX Venture Exchange under the ticker TOTC.P [1] - The announcement was made on January 13, 2026, indicating a partnership or transaction involving Usha Resources Ltd. [1]

Core Insights - FPT has been recognized as a Major Contender in the Everest Group Digital Transformation Services for Mid-market Enterprises PEAK Matrix® Assessment 2025 [1] - The assessment evaluates 24 global providers of digital transformation services specifically targeting mid-market enterprises [1] - Providers are categorized into Leaders, Major Contenders, Aspirants, and Star Performers based on their market impact, vision, and capabilities [1]

Core Insights - The Q4 earnings season began positively with JPMorgan and Delta Air Lines reporting favorable results, although both stocks fell over 2% due to cautious economic outlooks [1][2] JPMorgan's Q4 Results - JPMorgan reported Q4 sales of $45.79 billion, a 7% increase from $42.76 billion in the previous year, surpassing expectations of $45.69 billion [4] - The bank's net income was $13 billion, with adjusted EPS of $5.23, exceeding Q4 earnings expectations of $4.87 per share by 7% and rising 9% from $4.81 a year ago [6] - A 17% increase in market revenue, driven by fixed income, currencies, commodities, and equities, was a key growth factor, while investment banking continued to struggle [4][6] - JPMorgan's full-year sales increased 3% to $185.6 billion, with full-year EPS rising 1% to $20.02 [10] Delta Air Lines' Q4 Results - Delta's Q4 sales rose 3% to $16 billion, exceeding estimates of $15.62 billion, despite a 2% revenue reduction due to the U.S. government shutdown [8] - The airline reported a net income of $1.22 billion, with adjusted EPS of $1.55, slightly above estimates of $1.53 but down from $1.85 in the previous year [9] - Delta's full-year sales reached a record $63.4 billion, with management highlighting strong free cash flow generation of $4.6 billion [11] Economic Insights - JPMorgan's CEO noted the resilience of the U.S. economy but warned of geopolitical tensions and potential inflation challenges [2] - Delta indicated a bifurcation in consumer spending, with high-income travelers maintaining strong spending while price-sensitive consumers show signs of fatigue [3] Future Guidance - JPMorgan expects FY26 net interest income to rise to $103 billion, with projected sales of $190.86 billion and EPS of $20.97 [10] - Delta anticipates FY26 EPS between $6.50 and $7.50, indicating over 20% growth, with Q1 EPS expected at $0.50-$0.90 [12] Valuation and Investment Considerations - Both JPMorgan and Delta are considered attractively valued, with JPM trading at 15X forward earnings and Delta at 9X [13] - Analysts may find it appealing to buy into these stocks post-earnings selloff, provided economic outlooks and EPS revisions remain stable [14]

Core Viewpoint - Mitsubishi Electric Corporation is launching new trench silicon carbide metal-oxide-semiconductor field-effect transistor (SiC-MOSFET) bare dies aimed at enhancing power electronics equipment efficiency, particularly for electric vehicles and renewable energy systems [1][3]. Group 1: Product Launch - Starting January 21, Mitsubishi Electric will ship samples of four new SiC-MOSFET bare dies designed for power electronics applications [1]. - These bare dies are intended for use in electric vehicle traction inverters, onboard chargers, and renewable energy power supply systems [1]. Group 2: Market Trends - The market for power electronics equipment is projected to grow due to global decarbonization efforts [3]. - There is an increasing demand for power semiconductors with efficient bare dies that reduce power consumption while ensuring high performance [3]. Group 3: Exhibitions - Mitsubishi Electric will showcase the new SiC-MOSFET bare dies at the 40th Nepcon Japan R&D and Manufacturing show in Tokyo from January 21 to 23, along with other exhibitions in North America, Europe, China, and India [2].

Core Viewpoint - Harmony Biosciences is entering 2026 with significant momentum driven by three key factors: strong performance of WAKIX, a robust late-stage pipeline, and a strong financial profile [3][4]. Group 1: WAKIX Performance - WAKIX has shown five years of consecutive growth and profitability, with guidance for 2026 indicating over $1 billion in net revenue, positioning it to achieve blockbuster status this year [3]. Group 2: Late-Stage Pipeline - The company has five Phase III programs in the clinic targeting five distinct CNS indications, which are expected to provide multiple catalysts in the coming years [4]. Group 3: Financial Profile - Harmony Biosciences is characterized by a strong financial profile, indicating profitability and a solid foundation for future growth [4].

Core Viewpoint - Ford's CEO Jim Farley emphasized the necessity of a North American free trade deal for the automaker and the broader automotive industry, following U.S. President Trump's dismissal of the deal as "irrelevant" [1] Group 1 - The automotive industry is seeking a North American free trade agreement to enhance competitiveness and operational efficiency [1] - Jim Farley’s comments reflect the industry's concerns regarding trade policies and their impact on manufacturing and sales [1]

Company Overview - RxSight is focused on transforming cataract surgery outcomes through a new capability called adjustability, which has not previously existed in ophthalmology [2] - The company has grown to approximately 500 employees and has performed around 300,000 Light Adjustable Lens (LAL) procedures [3] Market Position - RxSight operates in about 1,100 ophthalmic offices and has trained over 2,500 surgeons [3] - The company has achieved a market share of approximately 10% in the U.S. premium intraocular lens (IOL) market [3] Recent Performance - RxSight reported a 12% year-over-year growth in procedures and a nearly 20% increase in its installed base [4] - The company announced the appointment of a new Chief Financial Officer, Mark Wilterding, who brings extensive experience in med tech and banking [4]

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Ohio, captioned Lingam v. Bath & Body Works, Inc., et al., No. 2:26-cv-00039 [3]. - Investors have until March 13, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Strategy - Bath & Body Works is a specialty retailer focusing on home fragrance and body care products, exploring product categories beyond its core business, including men's products, lip care, hair care, and laundry items [4]. - The company claimed that customers were responding favorably to its innovations and that its strategy was driving topline growth through category adjacencies [5]. Group 3: Stock Performance - On August 28, 2025, Bath & Body Works reported disappointing Q2 2025 results, cutting its full-year earnings guidance by $0.03 to a range of $3.28 to $3.53, leading to a stock drop of $2.18 per share, or 6.9% [6]. - Following the Q3 2025 results on November 20, 2025, which revealed that the strategy of pursuing adjacencies had not grown the customer base, the stock fell by $5.22 per share, or 24.8% [7].